Corey Cutler
YOU?
Author Swipe
View article: Early persistence of recipient stem-cells and T-cell dysregulation are associated with relapse after transplant in AML/MDS
Early persistence of recipient stem-cells and T-cell dysregulation are associated with relapse after transplant in AML/MDS Open
SUMMARY Hematopoietic stem cell transplantation (HSCT) offers the best curative option for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), yet relapse remains common. Current relapse detection methods are often too late fo…
View article: A multicenter phase 1 trial evaluating the safety and preliminary efficacy of revumenib as post-transplant maintenance after allogeneic hematopoietic cell transplant in patients with KMT2A-rearranged or NPM1-mutated acute leukemia
A multicenter phase 1 trial evaluating the safety and preliminary efficacy of revumenib as post-transplant maintenance after allogeneic hematopoietic cell transplant in patients with KMT2A-rearranged or NPM1-mutated acute leukemia Open
Background and Significance Allogeneic stem cell transplant (alloSCT) is a potentially curative post-remission therapy for patients with acute leukemia; however, chromosomal rearrangements involving the lysine methyltransferase 2A (KMT2A) …
View article: Efficacy of motixafortide plus G-CSF versus plerixafor plus G-CSF for stem cell mobilization and collection in multiple myeloma: A single-center comparative analysis and interim Results from a prospective study in poor mobilizers
Efficacy of motixafortide plus G-CSF versus plerixafor plus G-CSF for stem cell mobilization and collection in multiple myeloma: A single-center comparative analysis and interim Results from a prospective study in poor mobilizers Open
Introduction Stem cell collection after 4–8 cycles of induction therapy remains standard for multiple myeloma (MM), supporting autologous stem cell rescue/transplantation (ASCT) following high-dose melphalan. The recent growth of cell ther…
View article: Impact of graft versus host disease prophylaxis with post transplant cyclophosphamide on the prognostic value of HCT-CI
Impact of graft versus host disease prophylaxis with post transplant cyclophosphamide on the prognostic value of HCT-CI Open
Background: The hematopoietic cell transplantation specific comorbidity index (HCT-CI) is a crucial validated prognostic tool used to make baseline assessment for allogeneic hematopoietic cell transplantation (HCT). Since the results of BM…
View article: No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse Open
Acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) portends a dismal prognosis. One approach for reinvigorating a graft-vs-leukemia response is consolidation with donor lymphocyte infusions…
View article: Medication Adherence in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Medication Adherence in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Open
Introduction: Medication adherence is essential for treatment and recovery following hematopoietic stem cell transplantation (HSCT). However, limited data exist on the most effective methods to measure adherence and the factors influencing…
View article: Belumosudil for Chronic Graft-Versus-Host Disease: Analysis of Long-Term Results from the KD025-208 and ROCKstar Studies
Belumosudil for Chronic Graft-Versus-Host Disease: Analysis of Long-Term Results from the KD025-208 and ROCKstar Studies Open
Belumosudil is an oral selective rho-associated coiled-coil-containing protein kinase-2 (ROCK2) inhibitor approved for the treatment of chronic graft-versus-host disease (cGVHD) following an allogeneic hematopoietic cell transplant in pati…
View article: Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study
Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study Open
Belumosudil (KD025), an oral, selective, Rho-associated, coiled-coil–containing protein kinase 2 (ROCK2) inhibitor, is approved for third-line treatment of chronic graft-versus-host disease (cGVHD). Previous studies demonstrated that ROCK2…
View article: Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphoma
Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphoma Open
View article: Reduced incidence of relapse and graft-<i>versus</i>-host disease in acute myeloid leukemia after allogeneic hematopoietic cell transplantation
Reduced incidence of relapse and graft-<i>versus</i>-host disease in acute myeloid leukemia after allogeneic hematopoietic cell transplantation Open
Advances in HLA typing, conditioning regimens, GVHD prophylaxis/treatment, and supportive care have led to significant improvement in survival after allogeneic hematopoietic cell transplantation (alloHCT). Despite this progress, disease re…
View article: Introduction to <i>American Journal of Hematology</i> Supplement: Improving Initial Care for Acute <scp>GVHD</scp> Patients
Introduction to <i>American Journal of Hematology</i> Supplement: Improving Initial Care for Acute <span>GVHD</span> Patients Open
View article: Prehabilitation Exercise Training to Target Improved Muscle Strength in Pretransplant Patients Diagnosed With Multiple Myeloma: Protocol for a Pilot Randomized Controlled Trial
Prehabilitation Exercise Training to Target Improved Muscle Strength in Pretransplant Patients Diagnosed With Multiple Myeloma: Protocol for a Pilot Randomized Controlled Trial Open
Background Muscle mass and strength are severely compromised in patients diagnosed with multiple myeloma, such that the risk of poor overall survival increases as the prevalence of low muscle mass, also known as sarcopenia, increases. Addi…
View article: Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis
Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis Open
To examine the activity of ibrutinib in steroid-refractory chronic graft-versus-host disease (SR-cGVHD) after the US Food and Drug Administration approval, we conducted a multicenter retrospective study. Data were standardly collected (N =…
View article: Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202
Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202 Open
Post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis regimens are associated with very low rates of severe acute and chronic GVHD after hematopoietic cell transplant (HCT). However, concerns about card…
View article: Study Protocol: Predicting the Quality of Response to Specific Treatments (PQRST) in Chronic Graft-versus-Host Disease
Study Protocol: Predicting the Quality of Response to Specific Treatments (PQRST) in Chronic Graft-versus-Host Disease Open
NCT04431479.
View article: Microbiota signature of oral chronic graft-<i>versus</i>-host disease 6+ years after transplantation
Microbiota signature of oral chronic graft-<i>versus</i>-host disease 6+ years after transplantation Open
Not available.
View article: Comparison of treatment response measures in cutaneous sclerosis after allogeneic hematopoietic cell transplantation
Comparison of treatment response measures in cutaneous sclerosis after allogeneic hematopoietic cell transplantation Open
Cutaneous sclerosis, a highly morbid subtype of chronic graft-versus-host disease (GVHD), demonstrates limited treatment response under current National Institutes of Health (NIH) response measures. We explored novel sclerosis-specific res…
View article: A Positive Psychology Intervention in Allogeneic Hematopoietic Stem Cell Transplantation Survivors (PATH): A Pilot Randomized Clinical Trial
A Positive Psychology Intervention in Allogeneic Hematopoietic Stem Cell Transplantation Survivors (PATH): A Pilot Randomized Clinical Trial Open
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) survivors experience significant psychological distress and low levels of positive psychological well-being, which can undermine patient-reported outcomes (PROs), such a…
View article: Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor overall survival
Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor overall survival Open
The use of CD34+ selected stem cell boost (SCB) after allogeneic hematopoietic cell transplant (allo-HCT) has been increasing. Predictors of treatment failure after SCB, both in the context of poor graft function (PGF) or other settings, a…
View article: Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML Open
We conducted a phase 1 trial assessing safety and efficacy of prophylactic maintenance therapy with venetoclax and azacitidine (Ven/Aza) for patients with high-risk myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) undergoing re…
View article: Dental evaluation and clearance prior to allogeneic hematopoietic cell transplantation
Dental evaluation and clearance prior to allogeneic hematopoietic cell transplantation Open
Introduction Dental examination and stabilization are performed prior to allogeneic hematopoietic cell transplantation to decrease infection risk during neutropenia. Burden of dental disease and treatment need is not well characterized in …
View article: Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study
Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study Open
PURPOSE Allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS) improves overall survival (OS). We evaluated the impact of MDS genetics on the benefit of HCT in a biological assignment (donor v n…
View article: Medication Adherence in Patients with Hematologic Malignancies Who Are Hematopoietic Stem Cell Transplantation Survivors: A Qualitative Study
Medication Adherence in Patients with Hematologic Malignancies Who Are Hematopoietic Stem Cell Transplantation Survivors: A Qualitative Study Open
View article: Positive Psychological Well-Being in Hematopoietic Stem Cell Transplantation Survivors
Positive Psychological Well-Being in Hematopoietic Stem Cell Transplantation Survivors Open
View article: Feasibility of a positive psychology intervention (PATH) in allogeneic hematopoietic stem cell transplantation survivors: Randomized pilot trial design and methods
Feasibility of a positive psychology intervention (PATH) in allogeneic hematopoietic stem cell transplantation survivors: Randomized pilot trial design and methods Open
View article: P.104 Grade 3 meningioma survival, recurrence and functional outcomes in an international multicenter cohort
P.104 Grade 3 meningioma survival, recurrence and functional outcomes in an international multicenter cohort Open
Background: Meningiomas are the most common intracranial tumor, graded from 1 (benign) to 3 (malignant). The aim of this study was to identify clinical features associated with overall survival (OS), progression-free survival (PFS) and fun…
View article: Patient-reported treatment response in chronic graft-<i>versus</i>-host disease
Patient-reported treatment response in chronic graft-<i>versus</i>-host disease Open
Chronic graft vs. host disease (GVHD) treatment response is assessed using NIH Consensus criteria in clinical trials, and by clinician assessment in routine practice. Patient-reported treatment response is central to the experience of chro…
View article: Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse
Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse Open
Cytokine release syndrome (CRS) following haploidentical hematopoietic cell transplantation (HCT) resembles CRS after chimeric antigen receptor-T therapy. We conducted this single-center retrospective study to evaluate the association of p…
View article: Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD Open
The ability of posttransplant cyclophosphamide (PTCY) to facilitate haploidentical transplantation has spurred interest in whether PTCY can improve clinical outcomes in patients with HLA-matched unrelated donors undergoing peripheral blood…
View article: A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis
A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis Open
To develop a prognostic model for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients undergoing allo-HCT between 2000 and 2016 in the United States (the…